These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 10638214)

  • 1. [Remnant hyperlipidemia and gene polymorphism].
    Tada N
    Nihon Rinsho; 1999 Dec; 57(12):2789-94. PubMed ID: 10638214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased lipoprotein-remnant formation in chronic renal failure.
    Nestel PJ; Fidge NH; Tan MH
    N Engl J Med; 1982 Aug; 307(6):329-33. PubMed ID: 7088097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Triglyceride-rich lipoproteins as risk factors for atherosclerosis].
    Schwandt P
    Klin Wochenschr; 1990; 68 Suppl 22():54-8. PubMed ID: 2087080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between plasma HDL subclasses distribution and lipoprotein lipase gene HindIII polymorphism in hyperlipidemia.
    Long S; Tian Y; Zhang R; Yang L; Xu Y; Jia L; Fu M
    Clin Chim Acta; 2006 Apr; 366(1-2):316-21. PubMed ID: 16364275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Method for remnant lipoproteins--quantitative analysis of serum remnant-like particle cholesterol (RLP-C)].
    Nambu S
    Nihon Rinsho; 1999 Dec; 57(12):2740-4. PubMed ID: 10638206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo.
    Devlin CM; Lee SJ; Kuriakose G; Spencer C; Becker L; Grosskopf I; Ko C; Huang LS; Koschinsky ML; Cooper AD; Tabas I
    Arterioscler Thromb Vasc Biol; 2005 Aug; 25(8):1704-10. PubMed ID: 15905467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Impact of high remnant-like lipoproteins on the function of peripheral arterial endothelium in patients with hyperlipidemia and normolipidemia: estimation using Doppler flow analysis].
    Funada J; Sekiya M; Otani T; Watanabe K; Akutsu H
    J Cardiol; 2001 May; 37(5):267-76. PubMed ID: 11392896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risks for hyperlipidemia.
    Nestruck AC; Davignon J
    Cardiol Clin; 1986 Feb; 4(1):47-56. PubMed ID: 2871933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Peripheral remnant metabolism].
    Schmitz G; Kovacs E; Nowicka G
    Klin Wochenschr; 1990; 68 Suppl 22():32-7. PubMed ID: 2087076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia.
    Masuda D; Nakagawa-Toyama Y; Nakatani K; Inagaki M; Tsubakio-Yamamoto K; Sandoval JC; Ohama T; Nishida M; Ishigami M; Yamashita S
    Eur J Clin Invest; 2009 Aug; 39(8):689-98. PubMed ID: 19490064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal and gestational diabetic pregnancies. Lipids, lipoproteins and apolipoproteins.
    de Arcos F; Castelo-Branco C; Casals E; Sanllehy C; Cararach V
    J Reprod Med; 1998 Feb; 43(2):144-8. PubMed ID: 9513877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.
    Baggio G; Manzato E; Gabelli C; Fellin R; Martini S; Enzi GB; Verlato F; Baiocchi MR; Sprecher DL; Kashyap ML
    J Clin Invest; 1986 Feb; 77(2):520-7. PubMed ID: 3944267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum lipoproteins, apolipoproteins and intravenous fat tolerance in young athletes.
    Ericsson M; Johnson O; Tollin C; Furberg B; Backman C; Angquist K
    Scand J Rehabil Med; 1982; 14(4):209-12. PubMed ID: 7178868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Lipoproteins, apolipoproteins, lipoprotein lipase, hepatic triglyceride lipase and lecithin cholesterol acyltransferase in patients with nephrotic syndrome].
    Breier C; Lisch HJ; Drexel H; Braunsteiner H
    Schweiz Med Wochenschr; 1983 Jun; 113(25):909-13. PubMed ID: 6612272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetics of lipoprotein disorders.
    Breslow JL
    Circulation; 1993 Apr; 87(4 Suppl):III16-21. PubMed ID: 8462176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Remnant hyperlipidemia].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():112-8. PubMed ID: 11347041
    [No Abstract]   [Full Text] [Related]  

  • 20. Association between triglyceride-rich lipoprotein remnant receptor polymorphisms and lipid traits.
    Song J; Hong SH; Min W; Kim JQ
    Clin Biochem; 2000 Aug; 33(6):441-7. PubMed ID: 11074235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.